Phase 2TerminatedAge-related condition
X-82 to Treat Age-related Macular Degeneration
A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD
- Sponsor
- Tyrogenex (Industry)
- Enrollment
- 157 enrolled
- Conditions
- Age-Related Macular Degeneration (AMD); Macular Degeneration; Exudative Age-related Macular Degeneration; AMD; Macular Degeneration, Age-related, 10; Eye Diseases; Retinal Degeneration; Retinal Diseases
- Interventions
- X-82; Anti-VEGF; Placebo
- Ages
- adults, older adults
- Registry
- NCT02348359
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
Primary outcomes
- Mean Change in Visual Acuity Score From Day -1 to Week52
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered